Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPPAS: TRC105 plus pazopanib versus pazopanib alone in advanced angiosarcoma
2016-000485-34Phase 3Terminated
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- May 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in angiosarcoma comparing carotuximab + pazopanib with pazopanib alone (2 arms). Primary endpoint: Progression-free survival. Started May 2017; status: terminated.
02
Drugs
carotuximabpazopanib
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on 2016-000485-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000485-34.